健脾生血片联合右旋糖酐铁治疗孕期缺铁性贫血孕妇的临床效果

Clinical Effect of Jianpi Shengxue Tablets Combined with Iron Dextran on Pregnant Women with Iron Deficiency Anemia during Pregnancy

目的:观察健脾生血片联合右旋糖酐铁治疗孕期缺铁性贫血(IDA)孕妇的临床应用效果。方法:选取抚州市第一人民医院妇产科2020年1月—2022年12月收治的孕期IDA孕妇80例,以随机数字表法将其分为单一组与联合组,各40例。单一组仅给予孕妇右旋糖酐铁治疗,联合组在单一组的基础上联合健脾生血片治疗,均连续治疗3个月。观察两组孕妇的临床疗效;比较治疗前后两组孕妇贫血与铁代谢相关指标[血红蛋白(Hb)、红细胞计数(RBC)、红细胞平均体积(MCV)、血清铁(SI)、血清铁蛋白(SF)、可溶性转铁蛋白受体(sTfR)],免疫功能[成熟T细胞(CD3^(+))、辅助性T淋巴细胞(CD4^(+))、抑制性T淋巴细胞(CD8^(+))];比较两组不良妊娠结局与不良反应发生情况。结果:联合组总有效率(92.50%)高于单一组(75.00%),差异有统计学意义(P<0.05)。治疗3个月后,两组孕妇的Hb、RBC、MCV、SI、SF含量均较治疗前增加,且联合组均高于单一组,sTfR含量均较治疗前减少,且联合组低于单一组,差异均有统计学意义(P<0.05)。治疗3个月后,两组孕妇的CD3^(+)、CD4^(+)均较治疗前增加,且联合组均高于单一组,CD8^(+)均较治疗前减少,且联合组低于单一组,差异均有统计学意义(P<0.05)。联合组不良妊娠结局发生率(5.00%)低于单一组(20.00%),差异有统计学意义(P<0.05)。治疗期间两组孕妇不良反应发生率比较,差异无统计学意义(P>0.05)。结论:健脾生血片联合右旋糖酐铁治疗孕期IDA孕妇效果显著,能够缓解孕妇贫血与铁代谢相关指标,提高血红蛋白水平,增强免疫力,减少不良妊娠结局。

Objective:To observe the clinical effect of Jianpi Shengxue Tablets combined with Iron Dextran in the treatment of pregnant women with iron deficiency anemia(IDA).Method:A total of 80 IDA pregnant women admitted to the Department of Obstetrics and Gynecology of First People's Hospital of Fuzhou from January 2020 to December 2022 were selected.They were divided into the single group and the combined group using the random number method,with 40 cases in each group.The single group was treated with Iron Dextran only,the combined group was treated with Jianpi Shengxue Tablets on the basis of the single group,all of them were treated for 3 months.Clinical effects in the two groups were observed.The indexes related to anemia and iron metabolism[hemoglobin(Hb),red blood cell count(RBC),mean corpuscular volume(MCV),serum iron(SI),serum ferritin(SF)and soluble transferrin receptor(sTfR)]and immune function[mature T cells(CD3^(+)),helper T lymphocytes(CD4^(+))and inhibitory T lymphocytes(CD8^(+))]were compared between the two groups before and after treatment.Adverse pregnancy outcomes and adverse reactions were compared between the two groups.Result:The total effective rate of the combined group(92.50%)was higher than that of the single group(75.00%),the difference was statistically significant(P<0.05).After 3 months of treatment,the levels of Hb,RBC,MCV,SI and SF in both groups were increased,and the levels in the combined group were higher than those in the single group,sTfR levels were reduced,and sTfR level in the combined group was lower than that in the single group,the differences were statistically significant(P<0.05).After 3 months of treatment,CD3^(+)and CD4^(+)in both groups were increased,and those in the combined group were higher than those in the single group,CD8^(+)decreased,and CD8^(+)in the combined group was lower than that in the single group,the differences were statistically significant(P<0.05).The incidence of adverse pregnancy outcome in combined group(5.00%)was lower than that in single group(20.00%),the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion:Jianpi Shengxue Tablets combined with Iron Dextran have significant effects in the treatment of IDA in pregnant women,which can alleviate anemia and iron metabolism related indicators in pregnant women,improve hemoglobin level,enhance immunity,and reduce adverse pregnancy outcomes.